Prescription drug · BLA
Ahzantive (Aflibercept-mrbb) NDC 85006-2908
Aflibercept-mrbb 40 mg/mL · Injection, Solution · Intravitreal · Valorum Biologics, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 85006-2908-1 | 85006290801 | .05 mL in 1 VIAL, SINGLE-DOSE (85006-2908-1)Marketed from Oct 24, 2025 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ahzantive
- Generic name (nonproprietary)
- aflibercept-mrbb
- Active ingredients
- Aflibercept-mrbb — 40 mg/mL
- Dosage form
- Injection, Solution
- Route
- Intravitreal
- Labeler
- Valorum Biologics, LLCNDC labeler code 85006
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761378
- Marketing start
- Listing expires
- Other FDA classes
- Vascular Endothelial Growth Factor Inhibitors (Mechanism)
- Identifiers
- Product ID 85006-2908_42277606-719f-1fd3-e063-6394a90ad9d6SPL ID 42277606-719f-1fd3-e063-6394a90ad9d6SPL set ID 289e4b90-f741-c0f6-e063-6394a90a2068RxCUI 2706533, 2706541UNII 15C2VL427D
- Pharmacologic class
- Vascular Endothelial Growth Factor Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N485006290801followed by a unit qualifier and the quantityPackage 85006-2908-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
These highlights do not include all the information needed to use AHZANTIVE safely and effectively. See full prescribing information for AHZANTIVE. Initial U.S. Approval: 2024 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) AHZANTIVE is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) (1.1) Macular Edema Following Retinal Vein Occlusion (RVO) (1.2) Diabetic Macular Edema (DME) (1.3) Diab…
Excerpt only. Read the full label for complete information.
About NDC 85006-2908
- What is NDC 85006-2908?
- 85006-2908 is the product NDC for Ahzantive (aflibercept-mrbb), Aflibercept-mrbb 40 mg/mL injection, solution, listed with the FDA by Valorum Biologics, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Ahzantive (Aflibercept-mrbb).
- What is the active ingredient?
- Aflibercept-mrbb.
- Who is the labeler?
- Valorum Biologics, LLC, NDC labeler code 85006. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Ahzantive?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.